Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.79 |
| ▸ | PIM1 | P11309 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772101 | 0.88 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1120159 | 0.88 | PIK3CD (0.85) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1771488 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL456817 | 0.86 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL2214498 | 0.86 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1118623 | 0.85 | PIK3CA (0.60) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1960498 | 0.84 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1120074 | 0.83 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1772066 | 0.83 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 | |
| SCHEMBL1772173 | 0.82 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CGPIK3CBPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | claimed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | claimed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | claimed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | claimed |
| CN-102803217-A | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2012-11-28 | — | — | CN | claimed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | claimed |
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | claimed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | claimed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | claimed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PIK3CD 2147/4885PIK3CA 1025/4885PIK3CG 2507/4885 |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PIK3CD 2147/4885PIK3CA 1025/4885PIK3CG 2507/4885 |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | PIK3CD 111/4885PIK3CA 64/4885PIK3CG 181/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PIK3CD 2147/4885PIK3CA 1025/4885PIK3CG 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.